Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled trial of eprotirome in adults with heterozygous familial hypercholesterolemia on statin-based standard care
NL-OMON36068Phase 3Recruiting
- Sponsor
- Karo Healthcare AB
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eprotirome in familial hypercholesterolemia (FH) (3 arms), sponsored by Karo Healthcare AB. Primary endpoint: Percent change in LDL cholesterol from baseline to Week 12. Started Oct 2011; status: recruiting.
02
Drugs
eprotirome
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON36068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36068.